Industry reports
Editor highlights

Free Market Research Guides to Download

Pathology Analysis & Statistics, April 2014

You might be interested in: cancer, breast cancer, prostate cancer, more »

» Purchase Premium Reports

1-30 of 51 reports
NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

  • $ 3 500
  • Industry report
  • March 2014
  • by GBI Research

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool Summary GBI Research, the leading business intelligence ...

  • Industries : Pathology
  • Countries : World
Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth

  • $ 3 500
  • Industry report
  • February 2014
  • by GBI Research

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth Summary GBI Research, a leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : World
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

  • $ 3 500
  • Industry report
  • January 2014
  • by GBI Research

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape Summary GBI Research, has released the ...

  • Industries : Pathology
  • Countries : World
Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

  • $ 3 500
  • Industry report
  • December 2013
  • by GBI Research

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation Summary The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, ...

  • Industries : Pathology
  • Countries : World
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

  • $ 3 500
  • Industry report
  • December 2013
  • by GBI Research

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth Summary GBI Research has released the pharma ...

  • Industries : Pathology
  • Countries : World
Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

  • $ 3 500
  • Industry report
  • December 2013
  • by GBI Research

Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth Summary GBI Research, has released the pharma ...

  • Industries : Pathology
  • Countries : World, Japan, United States, Europe, Canada
Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use

Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use

  • $ 3 500
  • Industry report
  • November 2013
  • by GBI Research

Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use Summary GBI Research has released its pharmaceutical ...

  • Industries : Pathology
  • Countries : World, Australia, India, Japan, China, Asia
Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat

Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat

  • $ 3 500
  • Industry report
  • November 2013
  • by GBI Research

Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat Summary GBI Research has released its pharmaceutical ...

  • Industries : Pathology
  • Countries : World
Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation

  • $ 3 500
  • Industry report
  • October 2013
  • by GBI Research

Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation Summary GBI Research has released a new pharmaceutical report, “Frontier Pharma: Rheumatoid Arthritis ...

  • Industries : Pathology
  • Countries : World
Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

  • $ 3 500
  • Industry report
  • September 2013
  • by GBI Research

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies Summary GBI Research, the leading business ...

  • Industries : Pathology
  • Countries : World, Australia, China, Japan, India, Asia
Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

  • $ 3 500
  • Industry report
  • July 2013
  • by GBI Research

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Summary GBI Research, the leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : World
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease

  • $ 3 500
  • Industry report
  • May 2013
  • by GBI Research

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease Summary ...

  • Industries : Pathology
  • Countries : Australia, Japan, United States, India, World, Europe, China
Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson's Disease Treatment will Boost Market Despite Patent Cliff

Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson's Disease Treatment will Boost Market Despite Patent Cliff

  • $ 3 500
  • Industry report
  • March 2013
  • by GBI Research

Neurodegenerative Diseases Market to 2018 - New Product Entries in both Niche and Broader Parkinson's Disease Treatment will Boost Market Despite Patent Cliff Summary GBI Research, the leading business ...

  • Industries : Pathology
  • Countries : World, Italy, Germany, Japan, Spain, France, United States, United Kingdom, Europe
Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential

Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential

  • $ 3 500
  • Industry report
  • January 2013
  • by GBI Research

Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential Summary GBI Research has released its latest research, ?Acquired ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need

Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need

  • $ 3 500
  • Industry report
  • January 2013
  • by GBI Research

Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need Summary GBI Research, the leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, Europe, United States, United Kingdom
Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs% Major Market Share

Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs% Major Market Share

  • $ 3 500
  • Company report
  • November 2012
  • by GBI Research

Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share Summary GBI Research, the leading business intelligence provider, has released its latest ...

  • Industries : Pathology
  • Countries : World
Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans

Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans

  • $ 3 500
  • Industry report
  • September 2012
  • by GBI Research

Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans Summary GBI Research, the leading business intelligence provider has released its latest ...

  • Industries : Pathology
  • Countries : United States
Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise

Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise

  • $ 3 500
  • Industry report
  • July 2012
  • by GBI Research

Summary GBI Research, the leading business intelligence provider, has released its latest research, ?Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cance ...

  • Industries : Pathology
Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution

Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution

  • $ 3 500
  • Industry report
  • May 2012
  • by GBI Research

Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution Summary GBI Research, the leading business ...

  • Industries : Pathology
  • Countries : World
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

  • $ 3 500
  • Industry report
  • April 2012
  • by GBI Research

Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion Summary GBI Research, the leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : World
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies

Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies

  • $ 3 500
  • Industry report
  • April 2012
  • by GBI Research

Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies Summary GBI Research's report "Herpes Market to 2018 - Genericization Compels ...

  • Industries : Pathology
  • Countries : World
Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future

Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future

  • $ 3 500
  • Industry report
  • March 2012
  • by GBI Research

Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future Summary GBI Research's new report, ?Urological Disorders Therapeutics ...

  • Industries : Pathology
  • Countries : World
Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies

Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies

  • $ 3 500
  • Industry report
  • March 2012
  • by GBI Research

Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher's and Niemann-Pick Poised to Supersede Existing Therapies Summary GBI Research has released its latest research, ...

  • Industries : Pathology
  • Countries : World
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success

Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success

  • $ 3 500
  • Industry report
  • February 2012
  • by GBI Research

Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success Summary GBI Research, the leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : World
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

  • $ 3 500
  • Industry report
  • January 2012
  • by GBI Research

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules Summary GBI Research, ...

  • Industries : Pathology
  • Countries : World
ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

  • $ 3 500
  • Industry report
  • January 2012
  • by GBI Research

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance Summary GBI Research, the leading business intelligence provider, has ...

  • Industries : Pathology
  • Countries : World
Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma

Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma

  • $ 3 500
  • Industry report
  • January 2012
  • by GBI Research

Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma Summary GBI Research, the leading business intelligence provider, has released its latest ...

  • Industries : Pathology
  • Countries : World
Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma

  • $ 3 500
  • Industry report
  • December 2011
  • by GBI Research

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma Summary GBI Research, the leading business ...

  • Industries : Pathology
  • Countries : World
Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD

Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD

  • $ 3 500
  • Industry report
  • November 2011
  • by GBI Research

Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD Summary GBI Research's report, ?Clinical Trial Recruitment in Respiratory Diseases - Most Clinical ...

  • Industries : Pathology
  • Countries : Brazil, India, China, World
Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology

Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology

  • $ 3 500
  • Industry report
  • November 2011
  • by GBI Research

Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology Summary GBI Research, the leading business intelligence provider, has released ...

  • Industries : Pathology
  • Countries : Japan, World, United States, Europe

» View Public Reports

About 12 000 reports

U.S. Pharmaceutical Industry Analysis

  • Industry report
  • April 2014
  • 129 pages

... Of work are implicated as important causes of hypertension, as well as cvd., E.G. Job strain 96 schnall pl et al. Why the workplace and cardiovascular disease. In: schnall pl, belkic kl, landsbergis pa ...


» Read our Company Profiles

2 Companies

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.